IDIOPATHIC PULMONARY FIBROSIS MARKET

 

Market Overview:

               The market for idiopathic pulmonary fibrosis is anticipated to reach USD 5,723.69 million by 2027, recording a CAGR of 7.55% over the forecast period of 2022–2027. The market is likely to be worth USD 3,669.25 million in 2021. The respiratory system is impacted by severe coronavirus disease 2019 (COVID-19), which progresses to respiratory failure. It is believed that patients who already have chronic lung conditions such idiopathic pulmonary fibrosis (IPF) are at a higher risk of dying. A major portion of the acute exacerbation (AE) that IPF patients frequently experience is thought to be brought on by a respiratory viral infection.

Public authorities, governmental organisations, and major market players are placing more emphasis on the development of efficient treatment options as a result of the rise in the frequency and incidence rate of idiopathic pulmonary fibrosis (IPF) disease. As a result, the market is seeing an increase in research and development activities, which is anticipated to fuel market expansion over the study period. The pilot phase of COMPANION, the first clinical evaluation of a new digital therapy (DTx) for patients with IPF, a rare lung illness, was started by Curebase in April 2022.

Key Market Trends:

          An oral medication with antifibrotic, anti-inflammatory, and antioxidant properties is pirfenidone. Patients with idiopathic pulmonary fibrosis are prescribed this medication to reduce the disease's progression (IPF). Over the course of the study period, prominent market participants involved with the medicine pirfenidone are anticipated to increase their strategic initiatives like mergers, acquisitions, partnerships, and investments as well as their research and development efforts.

For instance, Sandoz announced the availability of generic pirfenidone in May 2022. This medication is an AB-rated (completely substitutable) alternative to Genentech's Esbriet and is used to treat people with idiopathic pulmonary fibrosis (IPF). Additionally, in June 2021, the business Genentech, a member of the Roche Group, reported that the United States Food and Drug Administration (FDA) had awarded Esbriet (pirfenidone) Priority Review and accepted its Supplemental New Drug Application (sNDA). Pirfenidone was added to the company's portfolio of oral solid pharmaceuticals in June 2022, according to an announcement made by another company, Accord Healthcare, Inc. This new medication is authorised to treat idiopathic pulmonary fibrosis and is therapeutically identical to Genentech's Esbriet (IPF)

Idiopathic pulmonary fibrosis (IPF) is a fatal fibrotic lung disease that typically affects middle-aged and older adults, according to a research report released in January 2022 titled "Idiopathic Pulmonary Fibrosis: An Update on Pathogenesis." It contributes significantly to morbidity and mortality. The financial burden of IPF is anticipated to continue growing in the foreseeable future as life expectancy rises. Adults in their middle years and older tend to develop IPF. The median age of newly diagnosed patients in the United States is 62 years, and 54% of them are men.

Comments

Popular posts from this blog

Shipping Containers Market Projected to Reach USD 12.77 Billion by 2030, Driven by E-commerce Growth and Cold-Chain Expansion

DATA CENTER POWER MARKET SIZE & SHARE ANALYSIS - GROWTH TRENDS & FORECASTS (2023 - 2028)

Second Hand Furniture Market Size & Share Analysis - Growth Trends & Forecasts (2023 - 2028)